| December 21, 2009
We spoke with Dr. Kent Willyard about his experience using Epocrates since it was introduced to healthcare professionals.
The European Commission (EU) has granted Bristol-Myers Squibb’s Daklinza (daclatasvir) approval for an all-oral drug regimen for the treatment of four genotypes of chronic hepatitis C infection.
An investigational drug that researchers hope will reverse nerve damage in patients with multiple sclerosis (MS) has been found to be safe and well tolerated in early trials.
The big question is whether it will work, researchers said.
The US Food and Drug Administration announced it will give priority review status to Amgen’s application to market ivabradine as a treatment for chronic heart failure.